| SUNDAY |
| 2:00 pm - 9:00 pm | Arrival and check-in |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Challenges and recent advances |
| Ken Duncan
Opening Remarks |
| Discussion Leader: Rick O'Brien (CDC) |
| Melvin Spigelman (Global Alliance for TB Drug Development)
"The challenge of TB drug development" |
| Stewart Cole (Institut Pasteur)
"Title to be advised" |
| MONDAY |
| 7:45 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | Targeting the cell wall |
| Discussion Leader: Patrick Brennan (Colorado State University) |
| Dean Crick (Colorado State University)
"Inhibition of isoprenoid biosynthesis" |
| Gurdyal Besra (University of Birmingham)
"Biochemical characterisation of pivotal enzymes involved in mycolic acid biosynthesis" |
| 10:30 am | Coffee Break |
| Tanya Parish (Barts and the London)
"Genetic analyses of mycolic acid biosynthesis genes and other short stories" |
| Edith Sim (Oxford University)
"N-acetyltransferase: An endogenous role in mycolic acid synthesis" |
| 12.45 pm | Group Photograph / Lunch |
| 1:30 pm - 4:00 pm | Free Time |
| 4:00 pm - 6:00 pm | Poster Session 1 |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Novel target identification and validation |
| Discussion Leader: Barbara Laughon (NIAID, NIH) |
| Jochen Wiesner (Jomaa Pharmaka)
"The mevalonate independent pathway of isoprenoid biosynthesis as target for new antimycobacterial agents" |
| Yossi Av-Gay (University of British Columbia)
"Serine/Threonine protein kinases of M. tuberculosis - key control signaling elements and unique drug targets for mycobacterial chemotherapy development" |
| Bert Klebl (Axxima)
"Target driven drug discovery in TB, employing the mycobacterial kinase PknG" |
| Prachee Chakhaiyar (CDFD, Hyderabad)
"Functional analyses of the chorismate utilizing enzymes of Mycobacterium tuberculosis: Potential drug targets" |
| TUESDAY |
| 7:45 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | Structure-based design |
| Discussion Leader: Jim Sacchettini (Texas A&M) |
| Clare Smith (Texas A&M)
"Structural genomics of novel persistence targets in M. tuberculosis" |
| Kurt Krause (University of Houston)
"Alanine Racemase as a template for TB Drug design" |
| 10.30 am | Coffee Break |
| David Leys (University of Leicester)
"Targeting mycobacterial cytochromes P450" |
| Shaun Lott (University of Auckland)
"Structural analysis of amino acid biosynthesis in M. tuberculosis"
|
| 12:30 pm | Lunch |
| 1:30 pm - 4:00 pm | Free Time |
| 4:00 pm - 6:00 pm | Poster Session 2 |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Identifying the lead compound |
| Discussion Leader: Christopher Lipinski (Pfizer) |
| Kelly Chibale (University of Cape Town)
"Privileged Scaffolds for Anti-TB Lead Discovery" |
| Michael Harn (Wellesley College)
"Preparation and properties of new sulfur-containing compounds against drug-resistant Tuberculosis. Chemical perspectives on identifying the lead" |
| Nicole Parrish (Johns Hopkins)
"Discovery and Investigation of the ß-sulfonylcarboxamides: a new class of compounds with selective activity against M. tuberculosis"
|
| WEDNESDAY |
| 7:45 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | Unraveling persistence and latency |
| Discussion Leader: John McKinney (Rockefeller University) |
| Thomas Dick (IMCB, Singapore)
"Hypoxia-induced dormancy" |
| Anthony Coates (St Georges Hospital Medical School)
"Persister M. tuberculosis as a target for new antibacterial agents" |
| 10:30 am | Coffee Break |
| Douglas Young (Imperial College)
"Antimycobacterial Drugs and the Host Immune Response" |
| Natalie Garton (Leicester University)
"Lipid inclusions in mycobacteria in vitro and in vivo: Their environmental regulation, composition and possible physiological roles" |
| 12:30 pm | Lunch |
| 1:30 pm - 4:00 pm | Free Time |
| 4:00 pm - 6:00 pm | Poster Session 3 |
| 6:00 pm | Dinner |
| 7.00 pm | Business Meeting |
| 7:30 pm - 9:30 pm | Application of global gene expression technology |
| Discussion Leader: Valerie Mizrahi (WITS) |
| Helena Boshoff (NIAID, NIH)
"Use of DNA microarrays to develop drug-specific gene signatures" |
| Joanna Betts (GlaxoSmithKline)
"Classifying isoniazid, thiolactomycin and triclosan treated Mycobacterium tuberculosis using DNA microarrays" |
| Eric Rubin (Harvard)
"Moving targets for TB therapeutics" |
| THURSDAY |
| 7:45 am - 8:30 am | Breakfast |
| 9:00 am - 12:30 pm | Lead optimisation |
| Discussion Leader: Barry Furr (AstraZeneca) |
| Leo Einck (Sequella Inc.)
"Second generation antibiotics from Ethambutol" |
| Clifton Barry (NIAID, NIH)
"Mechanism of action and lead optimization of 2-nitroimidazo-oxazoles for the treatment of tuberculosis" |
| 10:30 am | Coffee Break |
| R Shandil (AstraZeneca)
"Use of PKPD principles in lead optimisation" |
| Cindy Dowd (NIAID, NIH)
"Analogs of Thiolactomycin as antitubercular agents" |
| 12:30 pm | Lunch |
| 1:30 pm - 4:00 pm | Free Time |
| 4:00 pm - 6:00 pm | Poster Session 4 (optional) |
| 6:00 pm | Dinner |
| 7:30 pm - 9:30 pm | Beyond the laboratory |
| Discussion Leader: Pauline Lukey (GlaxoSmithKline) |
| Paul van Helden (University of Stellenbosch)
"Host and pathogen biomarkers for prediction of clinical outcome in patients with TB" |
| MS Jawahar (Tuberculosis Research Centre, Chennai)
"Shortening short course chemotherapy - the TRC experience"
|
| Denis Mitchison (St George's Hospital Medical School, London)
"Surrogate marker studies for new sterilising drugs"
|
| FRIDAY |
| 7:45 am - 8:30 am | Breakfast |
| 9:00 am | Departure |
